Top

Published in:

Open Access 01-12-2014 | Original research

Study of inter- and intra-observer reproducibility in the interpretation of [¹⁸F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment

Authors: Clothilde Pegard, Céline Gallazzini-Crépin, Joris Giai, Julien Dubreuil, Cécile Caoduro, Marie-Dominique Desruet, Julie Roux, Alex Calizzano, Daniel Fagret, Chloé Lamesa, Hatem Boulahdour, Jean-Philippe Vuillez

Published in: EJNMMI Research | Issue 1/2014

Abstract

Background

The aim of this study was to investigate the reproducibility of intra- and inter-observer interpretation of [¹⁸F]choline positron emission tomography/computed tomography examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment.

Methods

A total of 60 patients with biochemical recurrence after curative treatment were included in this bicentric study. The interpretations were based on a systematic analysis of several anatomic regions and all the four nuclear medicine physicians used identical result consoles. The examinations were interpreted with no knowledge of the patients' clinical context. Two months later, a second interpretation of all these examinations was performed using the same method, in random order.

Results

To evaluate local recurrences, when the prostate is in place, the results showed moderate inter- and intra-observer reproducibility: concordance of all 4 physicians has a Fleiss' kappa coefficient of 0.553 with a confidence interval of (0.425 to 0.693). For patients who had had a prostatectomy, there was excellent concordance for the negative examinations. For the lymphatic basin, inter- and intra-observer reproducibility was excellent with a Fleiss' kappa coefficient of 0.892 with a confidence interval of (0.788 to 0.975). The lymphatic sub-group analysis was also good. For the lymphatic groups in the right or left hemi-pelves, all Fleiss' kappa and Cohen's kappa coefficients are varying from 0.760 to 1 with narrow confidence intervals from (0.536 to 0.984) to (1 to 1) in favour of good/excellent inter-observer reproducibility. To evaluate bone metastasis, inter-observer reproducibility was good with a Fleiss' kappa coefficient of 0.703 and a confidence interval of (0.407 to 0.881).

Conclusion

Our study is at time the only one on the reproducibility of interpretation of [¹⁸F]choline positron emission tomography/computed tomography examinations, which is a key examination for the treatment of patients suffering biochemical recurrence of prostate cancer. Interpretation of the [¹⁸F]choline positron emission tomography/computed tomography examination is not so useful at prostate level in patients not previously treated with prostatectomy but has a great interest on patients treated by prostatectomy. It showed good concordance in the interpretation of sub-diaphragmatic lymphatic recurrences as well as in bone metastasis.

Available only for authorised users

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer Avr 2013, 49: 1374–1403. 10.1016/j.ejca.2012.12.027CrossRef

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J ClinFévr 2012, 62: 10–29. 10.3322/caac.20138CrossRef

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol Janv 2011, 59: 61–71. 10.1016/j.eururo.2010.10.039CrossRef

Beuzeboc P: Re: defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Eur Urol 2006, 50: 1121–1122. 10.1016/j.eururo.2006.08.020CrossRefPubMed

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281: 1591–1597. 10.1001/jama.281.17.1591CrossRefPubMed

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65: 965–974. 10.1016/j.ijrobp.2006.04.029CrossRefPubMed

Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, Thieme S, Cumming P, Klanke K, Tiling R, Bartenstein P, Hacker M: Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012, 39: 271–282. 10.1007/s00259-011-1970-2CrossRefPubMed

Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, Cozzarini C, Di Muzio N, Rigatti P, Fazio F, Messa C: Predictive factors of [¹¹C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37: 301–309. 10.1007/s00259-009-1253-3CrossRefPubMed

De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ: Preoperative staging of pelvic lymph nodes in prostate cancer by¹¹C-choline PET. J Nucl Med Off Publ Soc Nucl Med 2003, 44: 331–335.

10.

Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, Da Pozzo L, Bocciardi A, Rigatti P, Fazio F: Detection of lymph-node metastases with integrated [¹¹C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52: 423–429. 10.1016/j.eururo.2007.03.032CrossRefPubMed

11.

Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33: 159–174. 10.2307/2529310CrossRefPubMed

12.

Altman DG: Inter rater agreement. In Practical Statistics for Medical Research. Chapman & Hall/CRC, London; 1990:403–408.

13.

Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F: Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 2011, 60: 935–943. 10.1016/j.eururo.2011.07.060CrossRefPubMed

14.

Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker H-C, Souvatzogluou M, Gildehaus FJ, Wester HJ, Dresel S: Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007, 34: 45–53. 10.1007/s00259-006-0190-7CrossRefPubMed

15.

Igerc I, Kohlfürst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, Lind P: The value of¹⁸F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35: 976–983. 10.1007/s00259-007-0686-9CrossRefPubMed

16.

Souvatzoglou M, Weirich G, Schwarzenboeck S, Maurer T, Schuster T, Bundschuh RA, Eiber M, Herrmann K, Kuebler H, Wester HJ, Hoefler H, Gschwend J, Schwaiger M, Treiber U, Krause BJ: The sensitivity of [¹¹C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res Off J Am Assoc Cancer Res 2011, 17: 3751–3759. 10.1158/1078-0432.CCR-10-2093CrossRef

17.

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, Minn H: Kinetics of [¹¹C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004, 31: 317–324. 10.1007/s00259-003-1377-9CrossRefPubMed

18.

Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M, Kurhanewicz J, Manferrari F, Brunocilla E, Tonon C, Monetti N, Castellucci P, Fanti S, Coe M, Grigioni WF, Martorana G, Canini R, Barbiroli B: Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and¹¹C-choline PET/CT. Radiology 2007, 244: 797–806. 10.1148/radiol.2443061063CrossRefPubMed

19.

Reske SN, Blumstein NM, Glatting G: [¹¹C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008, 35: 9–17. 10.1007/s00259-007-0530-2CrossRefPubMed

Title: Study of inter- and intra-observer reproducibility in the interpretation of [18F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment
Authors: Clothilde Pegard
Céline Gallazzini-Crépin
Joris Giai
Julien Dubreuil
Cécile Caoduro
Marie-Dominique Desruet
Julie Roux
Alex Calizzano
Daniel Fagret
Chloé Lamesa
Hatem Boulahdour
Jean-Philippe Vuillez
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2014
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-014-0025-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Study of inter- and intra-observer reproducibility in the interpretation of [¹⁸F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Modification of intracellular glutathione status does not change the cardiac trapping of 64Cu(ATSM)

Feasibility of preoperative 125I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer

Quantitative intratumoural microdistribution and kinetics of 131I-huA33 antibody in patients with colorectal carcinoma

The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®